| Name | Title | Contact Details |
|---|
OPTIMIZED FLEETS. LOWER COSTS. ONE STRATEGIC PARTNER. As a strategic, brand-independent consulting partner we focus on empowering businesses to optimize their fleet management practices through: ✔Cutting-edge cost-saving initiatives ✔Real-time data analytics ✔Streamlined vendor management ✔Seamless intralogistics ✔Safeguarding assets and workforce ✔Increasing financial capacity ✔Optimizing efficiencies ✔Implementing responsible & sustainable practices Lets partner and find ways to optimize your fleet, experience 15x ROI, and drive operational efficiencies. Learn more at www.fleetteam.com
Hancock and Moore Fine Furniture
Unified Health Plan is an integrated group health plan, offering both level-funded and partially self-funded options for employers with 2 or more employees. We offer innovative value-based strategies that align provider and employer incentives to focus on the cost drivers of a health plan. Unified has a network of more than 20,000 doctors, hospital and pharmacies to provide you with comprehensive access throughout Kansas and more than 1,000,000 doctors, hospitals and pharmacies across the country. Members receive comprehensive benefits and have access to services such as care navigation and chronic disease management.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.